Evidence map›Paper›PMID 39257803›Full record

ArticlebioRxiv : the preprint server for biology2024

Validation studies and multi-omics analysis of Zhx2 as a candidate quantitative trait gene underlying brain oxycodone metabolite (oxymorphone) levels and behavior.

William B Lynch, Sophia A Miracle, Stanley I Goldstein, Jacob A Beierle, Rhea Bhandari, Ethan T Gerhardt, Ava Farnan, Binh-Minh Nguyen, Kelly K Wingfield, Ida Kazerani and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

William B LynchLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Sophia A MiracleLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Stanley I GoldsteinLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Jacob A BeierleLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.ORCID 0000-0001-6517-7614
Rhea BhandariLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Ethan T GerhardtLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Ava FarnanLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Binh-Minh NguyenLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Kelly K WingfieldLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.ORCID 0000-0002-9387-9063
Ida KazeraniLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Gabriel A SaavedraLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Olga AverinCenter for Human Toxicology, University of Utah Health, Salt Lake City, UT USA.
Britahny M BaskinLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.
Martin T FerrisDepartment of Genetics, University of North Carolina, Chapel Hill, NC USA.
Christopher A ReillyCenter for Human Toxicology, University of Utah Health, Salt Lake City, UT USA.
Andrew EmiliKnight Cancer Institute, Oregon Health & Science University, Portland, OR USA.
Camron D BryantLaboratory of Addiction Genetics, Department of Pharmaceutical Sciences and Center for Drug Discovery, Northeastern University, Boston, MA USA.

Funding

A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypesU01DA050243 · NIDA · NORTHEASTERN UNIVERSITY · PI BRYANT, CAMRON D · 2020 to 2023
$3.3M
Training Program on Development of Medications for Substance Use DisorderT32DA055553 · NIDA · NORTHEASTERN UNIVERSITY · PI Raymond G. Booth, Alexandros Makriyannis · 2022 to 2026
$1.3M
Ultra-High Precision Mass SpectrometerS10OD026807 · OD · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI EMILI, ANDREW · 2020 to 2020
$1.2M
The role of Zhx2 in CYP2D regulation, oxycodone metabolism, and opioid addiction model behaviors.F31DA056217 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LYNCH, WILLIAM · 2023 to 2024
$97k
NIDA NIH HHS F31 DA056217NIDA NIH HHS T32 DA055553NIDA NIH HHS U01 DA050243NIH HHS S10 OD026807
6 · The paper itself

Abstract

Sensitivity to the subjective reinforcing properties of opioids has a genetic component and can predict addiction liability of opioid compounds. We previously identified

Identifiers

PMID39257803
PMCPMC11383981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.